Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
“We are intrigued by the potential of RAD-51 inhibition, particularly due to early findings suggesting it could be helpful in treating lymphomas and other hematologic malignancies,” said Derek DiRocco, Ph.D., partner, RA Capital Management. “This promising mechanism, coupled with the demonstrated efficiency and expertise of...